메뉴 건너뛰기




Volumn 8, Issue , 2015, Pages 333-337

Antibiotic therapy and clostridium difficile infection – primum non nocere – first do no harm

Author keywords

Beta lactams; CDI; Prevention; SYN 004; Treatment; Vaccine

Indexed keywords

ACTIVATED CARBON; ANTIBIOTIC AGENT; BACTERIAL VACCINE; BETA LACTAMASE; CADAZOLID; CLOSTRIDIUM DIFFICILE VACCINE; CR 3123; FIDAXOMICIN; IC 84; METRONIDAZOLE; MK 3415A; PF 06425090; PROBIOTIC AGENT; REBIOTIX; SER 109; SMT 19969; SUROTOMYCIN; SYN 004; UNCLASSIFIED DRUG; VANCOMYCIN; VP 20621;

EID: 84941915127     PISSN: None     EISSN: 11786973     Source Type: Journal    
DOI: 10.2147/IDR.S87224     Document Type: Article
Times cited : (28)

References (47)
  • 1
    • 84908178824 scopus 로고    scopus 로고
    • The rise in Clostridium difficile infection incidence among hospitalized adults in the United States: 2001–2010
    • Reveles KR, Lee GC, Boyd NK, Frei CR. The rise in Clostridium difficile infection incidence among hospitalized adults in the United States: 2001–2010. Am J Infect Control. 2014;42(10):1028–1032.
    • (2014) Am J Infect Control , vol.42 , Issue.10 , pp. 1028-1032
    • Reveles, K.R.1    Lee, G.C.2    Boyd, N.K.3    Frei, C.R.4
  • 2
    • 0000795948 scopus 로고
    • Intestinal flora in new-born infants: With a description of a new pathogenic anaerobe, Bacillus difficilis
    • Hall IC, O’Toole E. Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Child. 1935;49:390–402.
    • (1935) Am J Dis Child , vol.49 , pp. 390-402
    • Hall, I.C.1    O’Toole, E.2
  • 3
    • 0028271412 scopus 로고
    • Bartlett JG. Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism. Clin Infect Dis. 1994;18(Suppl 4):S265–S272.
    • (1994) Clostridium Difficile , vol.18 , Issue.4 , pp. S265-S272
    • Bartlett, J.G.1
  • 4
    • 56849106496 scopus 로고    scopus 로고
    • The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing
    • Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 2008;6(11):e280.
    • (2008) Plos Biol , vol.6 , Issue.11
    • Dethlefsen, L.1    Huse, S.2    Sogin, M.L.3    Relman, D.A.4
  • 5
    • 79952756960 scopus 로고    scopus 로고
    • Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation
    • Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A. 2011;108(Suppl 1): 4554–4561.
    • (2011) Proc Natl Acad Sci U S A , vol.108 , pp. 4554-4561
    • Dethlefsen, L.1    Relman, D.A.2
  • 7
    • 77954581650 scopus 로고    scopus 로고
    • Etal. The changing epidemiology of Clostridium difficile infections
    • Freeman J, Bauer MP, Baines SD, etal. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev. 2010;23(3): 529–549.
    • (2010) Clin Microbiol Rev , vol.23 , Issue.3 , pp. 529-549
    • Freeman, J.1    Bauer, M.P.2    Baines, S.D.3
  • 8
    • 84897824639 scopus 로고    scopus 로고
    • Community-acquired Clostridium difficile infection: An increasing public health threat
    • Gupta A, Khanna S. Community-acquired Clostridium difficile infection: an increasing public health threat. Infect Drug Resist. 2014;7:63–72.
    • (2014) Infect Drug Resist , vol.7 , pp. 63-72
    • Gupta, A.1    Khanna, S.2
  • 9
    • 84868017013 scopus 로고    scopus 로고
    • . Burden of gastrointestinal disease in the United States: 2012 update
    • Peery AF, Dellon ES, Lund J, etal. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012;143(5): e1171–e1173.
    • (2012) Gastroenterology , vol.143 , Issue.5 , pp. e1171-e1173
    • Peery, A.F.1    Dellon, E.S.2    Lund, J.3
  • 10
    • 84860348952 scopus 로고    scopus 로고
    • Clinical and economic burden of Clostridium difficile infection in Europe: A systematic review of healthcare-facility-acquired infection
    • Wiegand PN, Nathwani D, Wilcox MH, Stephens J, Shelbaya A, Haider S. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect. 2012;81(1):1–14.
    • (2012) J Hosp Infect , vol.81 , Issue.1 , pp. 1-14
    • Wiegand, P.N.1    Nathwani, D.2    Wilcox, M.H.3    Stephens, J.4    Shelbaya, A.5    Haider, S.6
  • 11
    • 84880691277 scopus 로고    scopus 로고
    • . Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011
    • Chitnis AS, Holzbauer SM, Belflower RM, etal. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med. 2013;173(14):1359–1367.
    • (2013) JAMA Intern Med , vol.173 , Issue.14 , pp. 1359-1367
    • Chitnis, A.S.1    Holzbauer, S.M.2    Belflower, R.M.3
  • 12
    • 84936107665 scopus 로고    scopus 로고
    • The importance of considering different healthcare settings when estimating the burden of Clostridium difficile
    • Kuntz JL, Polgreen PM. The importance of considering different healthcare settings when estimating the burden of Clostridium difficile. Clin Infect Dis. 2014;60(6):831–836.
    • (2014) Clin Infect Dis , vol.60 , Issue.6 , pp. 831-836
    • Kuntz, J.L.1    Polgreen, P.M.2
  • 13
    • 84922693344 scopus 로고    scopus 로고
    • . Underdiagnosis of Clostridium difficile across Europe: The European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID)
    • Davies KA, Longshaw CM, Davis GL, etal. Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infect Dis. 2014; 14(12):1208–1219.
    • (2014) Lancet Infect Dis , vol.14 , Issue.12 , pp. 1208-1219
    • Davies, K.A.1    Longshaw, C.M.2    Davis, G.L.3
  • 14
    • 84941922680 scopus 로고    scopus 로고
    • Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013. Available from: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf. Accessed December 26, 2014.
  • 15
    • 0023296842 scopus 로고
    • Long-term prophylaxis of infection by selective decontamination in leukopenia and in mechanical ventilation
    • Clasener HA, Vollaard EJ, van Saene HK. Long-term prophylaxis of infection by selective decontamination in leukopenia and in mechanical ventilation. Rev Infect Dis. 1987;9(2):295–328.
    • (1987) Rev Infect Dis , vol.9 , Issue.2 , pp. 295-328
    • Clasener, H.A.1    Vollaard, E.J.2    Van Saene, H.K.3
  • 17
    • 84922906286 scopus 로고    scopus 로고
    • New perspectives in Clostridium difficile disease pathogenesis
    • Monaghan TM. New perspectives in Clostridium difficile disease pathogenesis. Infect Dis Clin North Am. 2015;29(1):1–11.
    • (2015) Infect Dis Clin North Am , vol.29 , Issue.1 , pp. 1-11
    • Monaghan, T.M.1
  • 18
    • 84856959278 scopus 로고    scopus 로고
    • Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics
    • Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother. 2012;67(3):742–748.
    • (2012) J Antimicrob Chemother , vol.67 , Issue.3 , pp. 742-748
    • Hensgens, M.P.1    Goorhuis, A.2    Dekkers, O.M.3    Kuijper, E.J.4
  • 19
    • 39449122789 scopus 로고    scopus 로고
    • Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients
    • Baxter R, Ray GT, Fireman BH. Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients. Infect Control Hosp Epidemiol. 2008;29(1):44–50.
    • (2008) Infect Control Hosp Epidemiol , vol.29 , Issue.1 , pp. 44-50
    • Baxter, R.1    Ray, G.T.2    Fireman, B.H.3
  • 20
    • 0031675366 scopus 로고    scopus 로고
    • Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam
    • Settle CD, Wilcox MH, Fawley WN, Corrado OJ, Hawkey PM. Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam. Aliment Pharmacol Ther. 1998;12(12):1217–1223.
    • (1998) Aliment Pharmacol Ther , vol.12 , Issue.12 , pp. 1217-1223
    • Settle, C.D.1    Wilcox, M.H.2    Fawley, W.N.3    Corrado, O.J.4    Hawkey, P.M.5
  • 21
    • 84866675037 scopus 로고    scopus 로고
    • . Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England
    • Wilcox MH, Shetty N, Fawley WN, etal. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England. Clin Infect Dis. 2012;55(8):1056–1063.
    • (2012) Clin Infect Dis , vol.55 , Issue.8 , pp. 1056-1063
    • Wilcox, M.H.1    Shetty, N.2    Fawley, W.N.3
  • 22
    • 3543110833 scopus 로고    scopus 로고
    • . Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea
    • Wilcox MH, Freeman J, Fawley W, etal. Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea. J Antimicrob Chemother. 2004;54(1): 168–172.
    • (2004) J Antimicrob Chemother , vol.54 , Issue.1 , pp. 168-172
    • Wilcox, M.H.1    Freeman, J.2    Fawley, W.3
  • 23
    • 79958827058 scopus 로고    scopus 로고
    • Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection
    • Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis. 2011;53(1):42–48.
    • (2011) Clin Infect Dis , vol.53 , Issue.1 , pp. 42-48
    • Stevens, V.1    Dumyati, G.2    Fine, L.S.3    Fisher, S.G.4    Van Wijngaarden, E.5
  • 24
    • 33846153776 scopus 로고    scopus 로고
    • Infectious Diseases Society of America; Society for Healthcare Epidemiology of America, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship
    • Dellit TH, Owens RC, McGowan JE Jr, Infectious Diseases Society of America; Society for Healthcare Epidemiology of America, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159–177.
    • (2007) Clin Infect Dis , vol.44 , Issue.2 , pp. 159-177
    • Dellit, T.H.1    Owens, R.C.2    McGowan, J.E.3
  • 25
    • 33747065605 scopus 로고    scopus 로고
    • . Impact of diversity of antibiotic use on the development of antimicrobial resistance
    • Sandiumenge A, Diaz E, Rodriguez A, etal. Impact of diversity of antibiotic use on the development of antimicrobial resistance. J Antimicrob Chemother. 2006;57(6):1197–1204.
    • (2006) J Antimicrob Chemother , vol.57 , Issue.6 , pp. 1197-1204
    • Sandiumenge, A.1    Diaz, E.2    Rodriguez, A.3
  • 27
    • 84859086665 scopus 로고    scopus 로고
    • . Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients
    • Alonso CD, Treadway SB, Hanna DB, etal. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2012;54(8):1053–1063.
    • (2012) Clin Infect Dis , vol.54 , Issue.8 , pp. 1053-1063
    • Alonso, C.D.1    Treadway, S.B.2    Hanna, D.B.3
  • 28
    • 84879879355 scopus 로고    scopus 로고
    • . Clostridium difficile infection among hematopoietic stem cell transplant recipients: Beyond colitis
    • Alonso CD, Marr KA. Clostridium difficile infection among hematopoietic stem cell transplant recipients: beyond colitis. Curr Opin Infect Dis. 2013;26(4):326–331.
    • (2013) Curr Opin Infect Dis , vol.26 , Issue.4 , pp. 326-331
    • Alonso, C.D.1    Marr, K.A.2
  • 29
    • 84875930188 scopus 로고    scopus 로고
    • . Epidemiology, risk factors, and outcomes of Clostridium difficile infection in kidney transplant recipients
    • Neofytos D, Kobayashi K, Alonso CD, etal. Epidemiology, risk factors, and outcomes of Clostridium difficile infection in kidney transplant recipients. Trans Infect Dis. 2013;15(2):134–141.
    • (2013) Trans Infect Dis , vol.15 , Issue.2 , pp. 134-141
    • Neofytos, D.1    Kobayashi, K.2    Alonso, C.D.3
  • 30
    • 84887259304 scopus 로고    scopus 로고
    • European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: Update of the treatment guidance document for Clostridium difficile infection
    • Debast SB, Bauer MP, Kuijper EJ, European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20(Suppl 2):1–26.
    • (2014) Clin Microbiol Infect , vol.20 , pp. 1-26
    • Debast, S.B.1    Bauer, M.P.2    Kuijper, E.J.3
  • 31
    • 84905057299 scopus 로고    scopus 로고
    • Polymer Alternative for CDI Treatment (PACT) investigators, etal. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: Results from two multinational, randomized, controlled trials
    • Johnson S, Louie TJ, Gerding DN, Polymer Alternative for CDI Treatment (PACT) investigators, etal. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis. 2014;59(3):345–354.
    • (2014) Clin Infect Dis , vol.59 , Issue.3 , pp. 345-354
    • Johnson, S.1    Louie, T.J.2    Gerding, D.N.3
  • 32
    • 84856718514 scopus 로고    scopus 로고
    • Fidaxomicin: A novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection
    • Venugopal AA, Johnson S. Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection. Clin Infect Dis. 2012;54(4):568–574.
    • (2012) Clin Infect Dis , vol.54 , Issue.4 , pp. 568-574
    • Venugopal, A.A.1    Johnson, S.2
  • 33
    • 84880509237 scopus 로고    scopus 로고
    • Advances in the treatment of Clostridium difficile with fidaxomicin: A narrow spectrum antibiotic
    • Sears P, Ichikawa Y, Ruiz N, Gorbach S. Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibiotic. Ann N Y Acad Sci. 2013;1291:33–41.
    • (2013) Ann N Y Acad Sci , vol.1291 , pp. 33-41
    • Sears, P.1    Ichikawa, Y.2    Ruiz, N.3    Gorbach, S.4
  • 34
    • 79551527297 scopus 로고    scopus 로고
    • , OPT-80-003 Clinical Study Group, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection
    • Louie TJ, Miller MA, Mullane KM, OPT-80-003 Clinical Study Group, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364(5):422–431.
    • (2011) N Engl J Med , vol.364 , Issue.5 , pp. 422-431
    • Louie, T.J.1    Miller, M.A.2    Mullane, K.M.3
  • 35
    • 84859007390 scopus 로고    scopus 로고
    • , OPT-80-004 Clinical Study Group, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: A double-blind, non-inferiority, randomised controlled trial
    • Cornely OA, Crook DW, Esposito R, OPT-80-004 Clinical Study Group, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet. 2012;12(4):281–289.
    • (2012) Lancet , vol.12 , Issue.4 , pp. 281-289
    • Cornely, O.A.1    Crook, D.W.2    Esposito, R.3
  • 36
    • 84863686440 scopus 로고    scopus 로고
    • Study 003/004 Teams, etal. Fidaxomicin versus vancomycin for Clostridium difficile infection: Meta-analysis of pivotal randomized controlled trials
    • Crook DW, Walker AS, Kean Y, Study 003/004 Teams, etal. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis. 2012;55(Suppl 2):S93–S103.
    • (2012) Clin Infect Dis , vol.55 , Issue.2 , pp. S93-S103
    • Crook, D.W.1    Walker, A.S.2    Kean, Y.3
  • 37
    • 84941881983 scopus 로고    scopus 로고
    • Wilcox MH, Hawkey PM, Patel B, Planche T, Stone S. Updated guidance on the management and treatment of Clostridium difficile infection; 2015. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/321891/Clostridium_difficile_management_and_treatment.pdf. 2013 Accessed January 17, 2015.
    • Wilcox, M.H.1    Hawkey, P.M.2    Patel, B.3    Planche, T.4    Stone, S.5
  • 38
    • 84875952150 scopus 로고    scopus 로고
    • Surawicz CM, Brandt LJ, Binion DG, etal. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478–498. [quiz 499].
    • Surawicz, C.M.1    Brandt, L.J.2    Binion, D.G.3
  • 39
    • 84939574142 scopus 로고    scopus 로고
    • Investigational new treatments for Clostridium difficile infection
    • Ivarsson ME, Leroux J, Castagner B. Investigational new treatments for Clostridium difficile infection. Drug Discov Today. 2015;20: 602–608.
    • (2015) Drug Discov Today , vol.20 , pp. 602-608
    • Ivarsson, M.E.1    Leroux, J.2    Castagner, B.3
  • 40
    • 67049107861 scopus 로고    scopus 로고
    • . P1A recombinant beta-lactamase prevents emergence of antimicrobial resistance in gut microflora of healthy subjects during intravenous administration of ampicillin
    • Tarkkanen AM, Heinonen T, Jõgi R, etal. P1A recombinant beta-lactamase prevents emergence of antimicrobial resistance in gut microflora of healthy subjects during intravenous administration of ampicillin. Antimicrob Agents Chemother. 2009;53(6):2455–2462.
    • (2009) Antimicrob Agents Chemother , vol.53 , Issue.6 , pp. 2455-2462
    • Tarkkanen, A.M.1    Heinonen, T.2    Jõgi, R.3
  • 42
    • 39349107697 scopus 로고    scopus 로고
    • . Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea
    • Chang JY, Antonopoulos DA, Kalra A, etal. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis. 2008;197(3):435–438.
    • (2008) J Infect Dis , vol.197 , Issue.3 , pp. 435-438
    • Chang, J.Y.1    Antonopoulos, D.A.2    Kalra, A.3
  • 43
    • 74849098405 scopus 로고    scopus 로고
    • . Treatment with monoclonal antibodies against Clostridium difficile toxins
    • Lowy I, Molrine DC, Leav BA, etal. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010; 362(3):197–205.
    • (2010) N Engl J Med , vol.362 , Issue.3 , pp. 197-205
    • Lowy, I.1    Molrine, D.C.2    Leav, B.A.3
  • 44
    • 77951015898 scopus 로고    scopus 로고
    • Safdar A. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010;362(15):1444–1445. [author reply 1445–1446].
    • Safdar, A.1
  • 45
    • 84884681207 scopus 로고    scopus 로고
    • Fecal microbiota transplantation and emerging treatments for Clostridium difficile infection
    • Gens KD, Elshaboury RH, Holt JS. Fecal microbiota transplantation and emerging treatments for Clostridium difficile infection. J Pharm Prac. 2013;26(5):498–505.
    • (2013) J Pharm Prac , vol.26 , Issue.5 , pp. 498-505
    • Gens, K.D.1    Elshaboury, R.H.2    Holt, J.S.3
  • 46
    • 84922540799 scopus 로고    scopus 로고
    • Immune-based treatment and prevention of Clostridium difficile infection
    • Zhao S, Ghose-Paul C, Zhang K, Tzipori S, Sun X. Immune-based treatment and prevention of Clostridium difficile infection. Hum Vaccin Immunother. 2014;10(12):3522–3530.
    • (2014) Hum Vaccin Immunother , vol.10 , Issue.12 , pp. 3522-3530
    • Zhao, S.1    Ghose-Paul, C.2    Zhang, K.3    Tzipori, S.4    Sun, X.5
  • 47
    • 78649807947 scopus 로고    scopus 로고
    • Management of Clostridium difficile infection: Thinking inside and outside the box
    • Gerding DN, Johnson S. Management of Clostridium difficile infection: thinking inside and outside the box. Clin Infect Dis. 2010;51(11): 1306–1313.
    • (2010) Clin Infect Dis , vol.51 , Issue.11 , pp. 1306-1313
    • Gerding, D.N.1    Johnson, S.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.